-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest statistics show that the incidence of kidney cancer is increasing year by year
.
In 2020, 73,587 patients were diagnosed with kidney cancer in China, surpassing the United States to become the country with the largest incidence of kidney cancer in the world
.
Although the level of early diagnosis and treatment of renal cancer has improved in recent years, in terms of diagnosis, about 60% of patients are still diagnosed with metastatic renal cancer at the first diagnosis or have distant metastasis during disease follow-up, which has serious consequences for patients' lives.
major threat
.
In terms of treatment, the current treatment response rate of advanced renal cancer has increased from about 30% in the era of targeted therapy to 50-70% in the era of targeted-immune combination.
Most of the effective patients will develop secondary resistance
.
The reason is that renal cancer is a highly genetically heterogeneous malignant tumor.
The biological behaviors and sensitivities of these tumor cells with different gene mutation spectrum and genetic phenotype are not the same .
Molecular characterization and molecular typing are the keys to improving the therapeutic efficacy of renal cancer and realizing precise treatment of renal cancer
.
In 2019, the American Clinical Proteomics Tumor Analysis Consortium (CPTAC) published the proteogenomic characteristics of 103 clear cell renal cancer patients, which provided the basis for precise treatment of renal cancer in European and American countries
.
However, due to the fact that the research population is concentrated on western renal cancer patients, and there is a gap between domestic patients in terms of treatment methods and drug use, this study cannot meet the urgent needs of domestic renal cancer clinical and basic research
.
In order to solve the above bottleneck problem, the team of Professor Ding Chen of the Institute of Human Phenotyping of Fudan University, the team of Professor Dingwei Ye from the Cancer Hospital Affiliated to Fudan University, and the team of Professor Jianyuan Zhao from the Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine jointly conducted a study of 232 kidney cancer patients in China.
Clear cell carcinomas were analyzed by proteogenomic sequencing combined with patient clinicopathological characteristics and survival data (Fig.
1A)
This study is the first to delineate the protein gene expression profile of Chinese clear cell renal cancer through a large sample cohort
.
The study found that the mutation frequency of key pathogenic genes of renal cancer in the Chinese population was significantly different from that in the European and American populations.
Figure 1.
Schematic diagram of proteogenomic analysis of 232 cases of clear renal cancer in Chinese population
Schematic diagram of multi-omics analysis; B.
Gene mutation spectrum and comparison between Chinese and Western cohorts; C.
Proteotyping
This achievement is the first time to describe the protein genome expression profile of clear cell renal cancer in the Chinese population, and to discover the differences in the mutation spectrum of key pathogenic genes of clear cell renal cancer between China and the West.
Molecular typing is performed based on the characteristics of the protein genome, which provides the basis for the precise treatment of clear kidney cancer.
theoretical basis
.
At the same time, this study also established a causal relationship between metabolic disorders and the occurrence and development of clear cell renal cancer, providing a new perspective for elucidating the mechanism of occurrence and development of clear cell renal cancer and precise treatment, and for the clinical phenomenon of renal cancer insensitivity to radiotherapy.
possible explanations
.
Feng Jinwen, Wu Xiaohui, Bai Lin, Zhu Lingli, Fudan University Affiliated Cancer Hospital Qu Yuanyuan, Xu Wenhao are the co-first authors of this article, Fudan University Human Phenotype Research Institute Professor Ding Chen, Fudan University Affiliated Cancer Hospital Professor Ye Dingwei, Professor Zhang Hailiang and Professor Zhao Jianyuan of Xinhua Hospital affiliated to Shanghai Jiaotong University are the co-corresponding authors of this article
.
This research was funded and supported by the Shanghai Municipal Science and Technology Major Project "International Human Phenotype Project (Phase I)", the Ministry of Science and Technology's Key R&D Program, the General and Key Projects of the National Natural Science Foundation of China, and the Shanghai Natural Science Foundation of China.
.
Original link: https://